PMID- 27756337
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20231111
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 9
IP  - 1
DP  - 2016 Oct 18
TI  - Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a 
      systematic review and meta-analysis.
PG  - 111
LID - 111
AB  - Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) 
      directed against the vascular endothelial growth factor (VEGF) or its receptors 
      have been investigated in several studies for the treatment of advanced gastric 
      cancer (GC). In the present study, we aimed to evaluate the efficacy and safety 
      of angiogenesis inhibitors in advanced GC. We searched published randomized 
      controlled trials (RCTs) comparing angiogenesis inhibitors with non-angiogenesis 
      inhibitors for the treatment of GC. MEDLINE, EMBASE, and the Cochrane Controlled 
      Trials Register were searched. The extracted data on progression-free survival 
      (PFS) and overall survival (OS) were measured in terms of hazard ratios (HR) and 
      corresponding 95 % confidence intervals (CIs). In addition, risk ratios (RR) and 
      corresponding 95 % CIs were pooled for objective response rate (ORR), disease 
      control rate (DCR), and risk of adverse events (AEs). Ten RCTs involving 2786 
      patients were included. Compared with non-angiogenesis inhibitor-containing 
      regimens, angiogenesis inhibitor-containing regimens resulted in a significant 
      improvement in OS (HR 0.80, 95 % CI 0.69-0.93, P = 0.004), prolonged PFS (HR 
      0.66, 95 % CI 0.51-0.86, P = 0.002), and superior ORR (RR 1.34, 95 % CI 
      1.09-1.65, P = 0.005) and DCR (RR 1.37, 95 % CI 1.17-1.61, P = 0.0001). 
      Angiogenesis inhibitors were associated with a greater number of AEs, but most of 
      these were predictable and manageable. However, hand-foot syndrome, diarrhea, and 
      gastrointestinal (GI) perforation were significantly increased in patients 
      treated with angiogenesis inhibitors. In summary, angiogenesis 
      inhibitor-containing regimens were superior to non-angiogenesis 
      inhibitor-containing regimens in terms of OS, PFS, RR, and DCR in patients with 
      advanced GC.
FAU - Yu, Jing
AU  - Yu J
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      No. 95 Yong An Road, Xicheng District, Beijing, 100050, China. 
      yujing026@ccmu.edu.cn.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      No. 95 Yong An Road, Xicheng District, Beijing, 100050, China.
FAU - Leung, Lai-Han
AU  - Leung LH
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for 
      Applied Research in Medicine and Health, Macau University of Science and 
      Technology, Taipa, Macau, 999078, China.
FAU - Liu, Lian
AU  - Liu L
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      No. 95 Yong An Road, Xicheng District, Beijing, 100050, China.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      No. 95 Yong An Road, Xicheng District, Beijing, 100050, China.
FAU - Yao, Xiaojun
AU  - Yao X
AD  - State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for 
      Applied Research in Medicine and Health, Macau University of Science and 
      Technology, Taipa, Macau, 999078, China. YXJunvip@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20161018
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Stomach Neoplasms/complications/*drug therapy/mortality
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC5070169
OTO - NOTNLM
OT  - Angiogenesis
OT  - Gastric cancer
OT  - Monoclonal antibodies
OT  - Tyrosine kinase inhibitors
EDAT- 2016/10/21 06:00
MHDA- 2017/12/06 06:00
PMCR- 2016/10/18
CRDT- 2016/10/21 06:00
PHST- 2016/08/12 00:00 [received]
PHST- 2016/10/08 00:00 [accepted]
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
PHST- 2016/10/18 00:00 [pmc-release]
AID - 10.1186/s13045-016-0340-8 [pii]
AID - 340 [pii]
AID - 10.1186/s13045-016-0340-8 [doi]
PST - epublish
SO  - J Hematol Oncol. 2016 Oct 18;9(1):111. doi: 10.1186/s13045-016-0340-8.